Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2024

This “Glycogen Synthase Kinase 3 (GSK3) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Glycogen Synthase Kinase 3 (GSK3) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Glycogen Synthase Kinase 3 (GSK3) Inhibitor Understanding

Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Overview

Glycogen synthase kinase 3 (GSK3) is a protein kinase that phosphorylated and inhibited glycogen synthase, the enzyme that catalyzes the transfer of glucose from UDPG to glycogen. Glycogen-synthase kinase-3 (GSK3) exists in two isoforms, termed a and ß, which are generated from distinct genes. GSK3 is active in its basal state and is inhibited upon phosphorylation at Ser9 in GSK-3ß and at Ser21 in GSK3a. GSK3 is a multifunctional protein kinase and has a broad range of substrates including signaling and structural proteins, as well as transcription factors. It is involved in various key biological processes, including glucose regulation, apoptosis, protein synthesis, cell signaling, cellular transport, gene transcription, proliferation, and intracellular communication. Accordingly, GSK-3 has been implicated in a wide variety of diseases and therefore specifically targeted for both therapeutic and imaging applications.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Glycogen Synthase Kinase 3 (GSK3) Inhibitor R&D. The therapies under development are focused on novel approaches for Glycogen Synthase Kinase 3 (GSK3) Inhibitor.

Glycogen Synthase Kinase 3 (GSK3) Inhibitor Emerging Drugs Chapters

This segment of the Glycogen Synthase Kinase 3 (GSK3) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glycogen Synthase Kinase 3 (GSK3) Inhibitor Emerging Drugs

Tideglusib: AMO Pharma Tideglusib is an orally available, small-molecule drug of the thiadiazolidinone class. It acts as an inhibitor of glycogen synthase kinase 3 (GSK3-ß), a widely studied tau kinase. Tideglusib is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta) and has neuroprotective effects. The drug is currently under clinical investigation for the treatment of congenital myotonic dystrophy and progressive supranuclearpalsy.

9 ING 41: Actuate Therapeutics9-ING-41 is a first-in-class, intravenously administered, maleimide-based small molecule potent selective GSK-3ß inhibitor with significant pre-clinical antitumor activity. 9-ING-41 has significant in vitro and in vivo activity as a single agent and/or in combination with standard cytotoxic chemotherapies in a spectrum of solid tumors and hematological malignancies including bladder, breast, glioblastoma, neuroblastoma, pancreatic, sarcomas, and renal cancers as well as lymphomas. 9-ING-41 is more selective for GSK-3ß than for other 320 related kinases when tested in a kinase screen.

Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Glycogen Synthase Kinase 3 (GSK3) Inhibitor

There are approx. 8+ key companies which are developing the Glycogen Synthase Kinase 3 (GSK3) Inhibitor. The companies which have their Glycogen Synthase Kinase 3 (GSK3) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, AMO Pharma.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Glycogen Synthase Kinase 3 (GSK3) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glycogen Synthase Kinase 3 (GSK3) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs.

Glycogen Synthase Kinase 3 (GSK3) Inhibitor Report Insights

• Glycogen Synthase Kinase 3 (GSK3) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Glycogen Synthase Kinase 3 (GSK3) Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs?
• How many Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Glycogen Synthase Kinase 3 (GSK3) Inhibitor?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Glycogen Synthase Kinase 3 (GSK3) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glycogen Synthase Kinase 3 (GSK3) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AMO Pharma
• Actuate Therapeutics
• Rock Creek Pharmaceuticals
• BCN Biosciences
• HitGen

Key Products

• Tideglusib
• 9 ING 41
• Anatabine
• BCN-057

Research program: glycogen synthase kinase 3 beta inhibitors